tert-butyl 2-[(4-nitrophenyl)amino]acetate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 2-[(4-nitrophenyl)amino]acetate
• 英文别名: N-(4-nitrophenyl)glycine tert-butyl ester；tert-butyl 2-(4-nitroanilino)acetate
• 化学式: C₁₂H₁₆N₂O₄
• 分子量: 252.27
• InChiKey: DLMMECNXMLGJFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-[(4-nitrophenyl)amino]acetate 、 2-[3-(3-methylphenyl)ureido]acetic acid 、 氯化亚砜 、 碳酸氢钠 在 氩 、 1,2-二氯乙烷 、 水 、 magnesium sulfate 、 silica 、 乙酸乙酯 作用下， 以 1,2-二氯乙烷 、 水 为溶剂， 10.0~40.0 ℃ 、359.97 kPa 条件下， 反应 0.17h， 以tert-butyl 2-{2-[3-(3-methylphenyl)ureido]-N-(4-nitrophenyl)acetamido}acetate (2.9 g), m.p. 152° C., is obtained的产率得到tert-butyl 2-{2-[3-(3-methylphenyl)ureido]-N-(4-nitrophenyl)acetamido}acetate
  参考文献：
  名称：

  N-phenylglycinamide CCK antagonists and pharmaceutical compositions

  摘要：

  化合物的公式：##STR1## 其中R.sub.1代表氢原子，烷基或烷氧羰基基团或苯基，可选地取代；R.sub.2代表烷氧基，可选地取代的环烷氧基，环烷基烷氧基，苯基烷氧基，多氟烷基氧基或肉桂氧基基团或基团--NR.sub.5 R.sub.6，R.sub.3代表苯基氨基基团，其中苯环可选地取代，可选地取代的苯基基团或萘基，吲哚基或喹啉基，R.sub.4代表取代的苯基基团，R.sub.5和R.sub.6，可以相同也可以不同，代表氢原子或烷基，可选地取代的苯基，吲哚基，环烷基烷基，环烷基或苯基烷基基团，或者R.sub.5和R.sub.6与它们连接的氮原子一起形成杂环，它们的制备和含有它们的药物产品。

  公开号：

  US05475106A1
• 作为产物：
  描述：

  tert-butyl 2-(N-formyl-4-nitroanilino)acetate 在 aluminum oxide 、 potassium fluoride 作用下， 反应 0.13h， 生成 tert-butyl 2-[(4-nitrophenyl)amino]acetate
  参考文献：
  名称：

  Microwave-assisted deformylation of N-aryl formamide by KF on basic Al2O3

  摘要：

  The formyl group was successfully removed from N-aryl formamide by KF on a solid support of basic Al2O3 in 4-20 min with microwave irradiation. The conditions mimic base-catalyzed hydrolysis of formamide and are compatible with carbamates and t-butyl esters, but not methyl, ethyl, and benzyl esters. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2007.04.127

文献信息

• Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US06627647B1

  公开（公告）日：2003-09-30

  A compound of Formula Ia wherein: R1 and R2, which are the same or different, are CF3; halogen; CN; branched or unbranched C1-8 alkyl; branched or unbranched C1-8 alkenyl; C3-8 cycloalkyl optionally substituted with OH, CN, or methoxy; C1-8 alkoxy; C1-4 alkyloxyalkyl; C1-8 alkylthio; C1-4 alkylthioalkyl; C1-8 dialkylamino; C1-4 dialkylaminoalkyl; CO2R4 where R4 is C1-4 alkyl or C1-4 alkenyl optionally substituted with carbocyclyl or heterocyclyl; or aryl or heterocyclyl connected to the imidazole in any position that makes a stable bond wherein the aryl or the heterocyclyl thereof is optionally substituted with halogen, C1-4 alkyl, C1-4 alkenyl, CN, Me2N, CO2Me, OMe, aryl, heterocyclyl, or R4; L is —NHC(O)—; —NHC(O)O—; —NHC(O)C(O)—; —NHC(S)—; —NH—; —NHC(O)NH—; —NHC(S)NH—; —NHCH2—; —NHCH(R5)—, wherein R5 is H, CN, C1-6 alkyl, C1-6 alkyloxyalkyl, C1-6 alkylthioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkylsulfonylalkyl, C3-6 cycloalkyl, heterocyclyl, or aryl optionally substituted with a halogen, C1-4 alkyl, CN, Me2N, CO2Me, or OMe; or —NHC(R5)-lower alkyl; and R3 is C1-8 alkyl; C1-8 alkyloxy; C1-8 alkylthio; C1-8 alkylamino; C1-4 alkoxyalkyl; C1-4 alkylthioalkyl; C1-4 alkylaminoalkyl; C1-4 dialkylaminoalkyl; —CO2R6; —N(R6)2; —NH(R6); —C(O)R6; —OR6; S(O)nR6, wherein n is 0, 1, or 2; —SO2NHR6; —SO2N(R6)2; or carbocyclyl or heterocyclyl, wherein the carbocyclyl or heterocyclyl thereof is optionally substituted with one or more of the following: halogen, —CN, —NO2, —SO2NH2, CF3, OCF3, OC1-4alkyl, OC3-5alkenyl, CO2C1-2alkyl, SMe, NMe2, R6, or O(CH2)pR7, where p is 3 or 4 and R7 is CN, CO2Me, 2-(1,3-dioxolanyl), OH, or OC6H5, wherein: R6 is phenyl, heterocyclyl, C3-6 cycloalkyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkyloxyalkyl, C1-6 alkylthioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkylsulfonylalkyl, or C2-6 alkynyl and R6 is optionally substituted with halogen, —OH, alkyloxy, —CN, —COO-lower alkyl, —CONH-lower alkyl, —CON(lower alkyl)2, dialkylamino, phenyl, or heterocyclyl, or a pharmaceutically acceptable derivative thereof.

  其中一种化合物的化学式为：R1和R2，可以相同也可以不同，可以是CF3；卤素；CN；支链或非支链的C1-8烷基；支链或非支链的C1-8烯基；C3-8环烷基，可选择性地取代为OH、CN或甲氧基；C1-8烷氧基；C1-4烷氧基烷基；C1-8烷硫基；C1-4烷硫基烷基；C1-8双烷基胺基；C1-4双烷基胺基烷基；CO2R4，其中R4是C1-4烷基或C1-4烯基，可选择性地取代为碳环烷基或杂环烷基；或芳基或杂环烷基与咪唑环连接在使其稳定键的任何位置，其中芳基或其杂环烷基可选择性地取代为卤素、C1-4烷基、C1-4烯基、CN、Me2N、CO2Me、OMe、芳基、杂环烷基或R4；L为—NHC(O)—；—NHC(O)O—；—NHC(O)C(O)—；—NHC(S)—；—NH—；—NHC(O)NH—；—NHC(S)NH—；—NH —；—NHCH(R5)—，其中R5为H、CN、C1-6烷基、C1-6烷氧基烷基、C1-6烷硫基烷基、C1-6烷基亚砜基烷基、C1-6烷基砜基烷基、C3-6环烷基、杂环烷基或芳基，可选择性地取代为卤素、C1-4烷基、CN、Me2N、CO2Me或OMe；或—NHC(R5)-较低烷基；R3为C1-8烷基；C1-8烷氧基；C1-8烷硫基；C1-8烷胺基；C1-4烷氧基烷基；C1-4烷硫基烷基；C1-4烷胺基烷基；C1-4双烷基胺基烷基；—CO2R6；—N(R6)2；—NH(R6)；—C(O)R6；—OR6；S(O)nR6，其中n为0、1或2；—SO2NHR6；—SO2N(R6)2；或碳环烷基或杂环烷基，其中其碳环烷基或杂环烷基可选择性地取代为以下一种或多种：卤素、—CN、—NO2、—SO2NH2、 、O 、OC1-4烷基、OC3-5烯基、CO2C1-2烷基、SMe、NMe2、R6或O(CH2)pR7，其中p为3或4，R7为CN、CO2Me、2-(1,3-二氧杂环丙基)、OH或OC6H5；其中：R6为苯基、杂环烷基、C3-6环烷基、C1-6烷基、C2-6烯基、C1-6烷氧基烷基、C1-6烷硫基烷基、C1-6烷基亚砜基烷基、C1-6烷基砜基烷基或C2-6炔基，R6可选择性地取代为卤素、—OH、烷氧基、—CN、—COO-较低烷基、—CONH-较低烷基、—CON(较低烷基)2、双烷基胺基、苯基或杂环烷基，或其药用接受的衍生物。
• US5475106A
  申请人：——

  公开号：US5475106A

  公开（公告）日：1995-12-12
• US6627647B1
  申请人：——

  公开号：US6627647B1

  公开（公告）日：2003-09-30
• [EN] SUBSTITUTED 1-(4-AMINOPHENYL)IMIDAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS<br/>[FR] 1-(4-AMINOPHENYL)IMIDAZOLES SUBSTITUES ET LEUR UTILISATION COMME AGENTS ANTI-INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2001070703A2

  公开（公告）日：2001-09-27

  A compound of Formula (Ia) or (Ib) wherein R1 and R2, which may be the same or different, are CF3; halogen; CN; branched or unbranched C1-8 alkyl; branched or unbranched C1-8 alkenyl; C3-8 cycloalkyl optionally substituted with OH, CN, or methoxy; C1-8 alkoxy; C1-4 alkyloxyalkyl; C1-8 alkylthio; C1-4 alkylthioalkyl; C1-8 dialkylamino; C1-4 dialkylaminoalkyl; CO2R4 where R4 is C1-4 alkyl or C1-4 alkenyl optionally substituted with carbocyclyl or heterocyclyl; aryl or heterocyclyl connected to the imidazole in any position that makes a stable bond which aryl or heterocyclyl is optionally substituted with halogen, C1-4 alkyl, C1-4 alkenyl, CN, Me2N, CO2Me, OMe, aryl, heterocyclyl, or R4; L is -NHC(O)-; -NHC(O)O-; -NHC(O)C(O)-; -NHC(S)-; -NH-; -NHC(O)NH-; -NHC(S)NH-; -NHCH2-; -NHCH(R5)- where R5 is H, CN, C1-6 alkyl, C1-6 alkyloxyoalkyl C1-6 alkythioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkysulfonylalkyl, C3-6 cycloalkyl, heterocyclyl, or aryl optionally substituted with a halogen, C1-4 alkyl, CN, Me2N, CO2Me, or OMe; or L is -NHC(R5)-lower alkyl; R3 is C1-8 alkyl; C1-8 alkyloxy; C1-8 alkylthio; C1-8 alkylamino; C1-4 alkoxyalkyl; C1-4 alkylthioalkyl; C1-4 alkylaminoalkyl; C1-4 dialkylalkylaminoalkyl; carbocyclyl or heterocyclyl, which carbocyclyl or heterocyclyl is optionally substituted with one or more of the following: halogen, -CN, -NO2, -SO2NH2, or R6 (where R6 is phenyl, heterocyclyl, C3-6 cycloalkyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkyloxyalkyl, C1-6 alkylthioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkylsulfonylalkyl, or C2-6 alkynyl) and R6 is optionally substituted with halogen, -OH, alkyloxy, -CN, -COO-lower alkyl, -CONH-lower alkyl, -CON (lower alkyl)2, dialkylamino, phenyl, or heterocyclyl; or R3 is -CO2R6; -N(R6)2; -NH(R6); -C(O)R6; -OR6; S(O)nR6 where n is O, 1, or 2; -SO2NHR6; or -SO2N(R6)2; or a pharmaceutically acceptable derivative thereof.